Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study.
SARS coronavirus
combination therapy
disease control
infection
virus classification
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
02
04
2024
received:
19
03
2024
accepted:
03
04
2024
medline:
15
4
2024
pubmed:
15
4
2024
entrez:
15
4
2024
Statut:
ppublish
Résumé
This study aims to assess the safety, virological, and clinical outcomes of convalescent plasma transfusion (CPT) in immunocompromised patients hospitalized for coronavirus disease 2019 (COVID-19). We conducted a retrospective multicenter cohort study that included all immunosuppressed patients with COVID-19 and RNAemia from May 2020 to March 2023 treated with CPT. We included 81 patients with hematological malignancies (HM), transplants, or autoimmune diseases (69% treated with anti-CD20). Sixty patients (74%) were vaccinated, and 14 had pre-CPT serology >264 BAU/mL. The median delay between symptom onset and CPT was 23 days [13-31]. At D7 post-CPT, plasma PCR was negative in 43/64 patients (67.2%), and serology became positive in 25/30 patients (82%). Post-CPT positive serology was associated with RNAemia negativity (p < 0.001). The overall mortality rate at D28 was 26%, being higher in patients with non-B-cell HM (62%) than with B-cell HM (25%) or with no HM (11%) (p = 0.02). Patients receiving anti-CD20 without chemotherapy had the lowest mortality rate (8%). Positive RNAemia at D7 was associated with mortality at D28 in univariate analysis (HR: 3.05 [1.14-8.19]). Eight patients had adverse events, two of which were severe but transient. Our findings suggest that CPT can abolish RNAemia and ameliorate the clinical course in immunocompromised patients with COVID-19.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29603Informations de copyright
© 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS‐CoV‐2 in immunocompromised individuals. Immunity. 2022;55(10):1779‐1798.
Khoury E, Nevitt S, Madsen WR, Turtle L, Davies G, Palmieri C. Differences in outcomes and factors associated with mortality among patients with SARS‐CoV‐2 infection and cancer compared with those without cancer. JAMA Network Open. 2022;5(5):e2210880.
Trøseid M, Hentzien M, Ader F, et al. Immunocompromised patients have been neglected in COVID‐19 trials: a call for action. Clin Microbiol Infect. 2022;28(9):1182‐1183.
Najjar‐Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high‐risk patients. Clin Infect Dis. 2023;76(3):e342‐e349.
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid‐19. N Engl J Med. 2021;384(8):693‐704.
Abani O, Abbas A, Abbas F, et al. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID‐19 (RECOVERY): a randomised, controlled, open‐label, platform trial. Lancet. 2021;397(10285):1637‐1645.
Abani O, Abbas A, Abbas F, et al. RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID‐19 (RECOVERY): a randomised, controlled, open‐label, platform trial and updated meta‐analysis. Lancet. 2022;400(10349):359‐368.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid‐19: final report. N Engl J Med. 2020;383(19):1813‐1826.
Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS‐CoV‐2. Lancet Infect Dis. 2022;22(11):e311‐e326.
Natarajan H, Crowley AR, Butler SE, et al. Markers of polyfunctional SARS‐CoV‐2 antibodies in convalescent plasma. mBio. 2021;12(2):e00765‐21.
Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid‐19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.
Abani O, Abbas A, Abbas F, et al. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID‐19 (RECOVERY): a randomised controlled, open‐label, platform trial. Lancet. 2021;397(10289):2049‐2059.
Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid‐19 severe pneumonia. N Engl J Med. 2021;384(7):619‐629.
Misset B, Piagnerelli M, Hoste E, et al. Convalescent plasma for Covid‐19–induced ARDS in mechanically ventilated patients. N Engl J Med. 2023;389(17):1590‐1600.
Biernat MM, Kolasińska A, Kwiatkowski J, et al. Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID‐19. Viruses. 2021;13(3):436.
Hueso T, Godron AS, Lanoy E, et al. Convalescent plasma improves overall survival in patients with B‐cell lymphoid malignancy and COVID‐19: a longitudinal cohort and propensity score analysis. Leukemia. 2022;36(4):1025‐1034.
Senefeld JW, Franchini M, Mengoli C, et al. COVID‐19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta‐analysis. JAMA Network Open. 2023;6(1):e2250647.
Denkinger CM, Janssen M, Schäkel U, et al. Anti‐SARS‐CoV‐2 antibody‐containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID‐19: a randomized clinical trial. Nature Cancer. 2023;4(1):96‐107.
Lacombe K, Hueso T, Porcher R, et al. Use of covid‐19 convalescent plasma to treat patients admitted to hospital for covid‐19 with or without underlying immunodeficiency: open label, randomised clinical trial. BMJ Medicine. 2023;2(1):e000427.
Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676‐682.
Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID‐19 clinical research. Lancet Infect Dis. 2020;20(8):e192‐e197.
Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS‐CoV‐2 infection. Nature Med. 2021;27(11):2032‐2040.
Haute Autorité de Santé [Internet]. L'analyse des évènements indésirables associés aux soins (EIAS): mode d'emploi. 2023. https://www.has-sante.fr/jcms/p_3293652/fr/l-analyse-des-evenements-indesirables-associes-aux-soins-eias-mode-d-emploi
Hagman K, Hedenstierna M, Rudling J, et al. Duration of SARS‐CoV‐2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID‐19: a cohort study. Diagn Microbiol Infect Dis. 2022;102(3):115595.
Wang C, Li Y, Kaplonek P, et al. The kinetics of SARS‐CoV‐2 antibody development is associated with clearance of RNAemia. mBio. 2022;13(4):e01577‐22.
Lan L, Xu D, Ye G, et al. Positive RT‐PCR test results in patients recovered from COVID‐19. JAMA. 2020;323(15):1502‐1503.
Focosi D, Senefeld JW, Joyner MJ, et al. Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses. Br J Haematol. 2023;200(2):22‐24.
Dimeglio C, Migueres M, Bouzid N, et al. Antibody titers and protection against omicron (BA.1 and BA.2) SARS‐CoV‐2 infection. Vaccines. 2022;10(9):1548.
Joyner MJ, Bruno KA, Klassen SA, et al. Safety update. Mayo Clin Proc. 2020;95(9):1888‐1897.
Yamamoto S, Mizoue T, Ohmagari N. Analysis of previous infection, vaccinations, and anti‐SARS‐CoV‐2 antibody titers and protection against infection with the SARS‐CoV‐2 Omicron BA.5 variant. JAMA Network Open. 2023;6(3):e233370.